Patents by Inventor Eneda Toska

Eneda Toska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF KMT2D FOR THE TREATMENT OF CANCER
    Publication number: 20220307031
    Abstract: The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.
    Type: Application
    Filed: February 10, 2022
    Publication date: September 29, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jose Baselga, Eneda Toska, Scott Armstrong
  • Inhibition of KMT2D for the treatment of cancer
    Patent number: 11248229
    Abstract: The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 15, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jose Baselga, Eneda Toska, Scott Armstrong
  • INHIBITION OF KMT2D FOR THE TREATMENT OF CANCER
    Publication number: 20190270997
    Abstract: The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.
    Type: Application
    Filed: May 10, 2019
    Publication date: September 5, 2019
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jose Baselga, Eneda Toska, Scott Armstrong